Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
← catalyst calendarNCT05523947 · readout in 590 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
147estimated
Sites
19
Countries
Australia, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-26 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HER2-Positive Solid Tumor
Intervention
- Drug: YH32367
Primary outcomes
what the primary-completion date above is the date OFTreatment-emergent adverse events (TEAEs) up to Day 21
measured in dose escalation part, an average of 21 days
Objective Response Rate (ORR)
measured through dose expansion part completion, approximately 2.5 year
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed